Abstract:Lay Summary What does this mean for patients? Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a type of coronavirus that causes coronavirus disease 2019 (COVID-19). Spread of SARS-CoV-2 led to the COVID-19 pandemic and a global threat to public health. Different variants of SARS-CoV-2 have developed as the virus changes over time. Omicron is one such variant. Patients with systemic autoimmune rheumatic diseases (SARDs), such as rheumatoid arthritis, systemic lupus erythematosus and Sjogren's syndrome, are often treated with drugs called immunosuppressants. Immunosuppressants make the immune system less active, meaning that it is harder to defend against diseases such as COVID-19. As a result, SARD patients are at higher risk of developing severe COVID-19. We performed a study to describe the characteristics and immune responses of SARD patients with COVID-19 Omicron infection in China. We found that SARD patients had fewer antibodies against Omicron than healthy people. We also found that lupus patients who used biologic drugs had a lower antibody level than those using glucocorticoids (steroids) and/or hydroxychloroquine. Importantly, SARD patients who had at least two doses of SARS-CoV-2 vaccine had higher levels of antibodies than unvaccinated patients. These findings suggest that patients with SARDs have a lower antibody response after Omicron infection than healthy people, meaning that their immune systems are less able to defend against future re-infection. Our data therefore support the importance of COVID-19 booster vaccination among patients with SARDs. Objectives The surge of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant Omicron infections has affected most Chinese residents at the end of 2022, including a number of patients with systemic autoimmune rheumatic diseases (SARDs). Methods To investigate the antibody level of the Omicron variant in SARD patients after SARS-CoV-2 Omicron infection, we tested BA.5.2 and BF.7 Omicron variant IgG antibody levels using ELISA on blood samples collected from 102 SARD patients and 19 healthy controls (HCs). The type of SARD, demographics, concurrent treatment, doses of SARS-CoV-2 vaccines and outcomes were also recorded. Results A total of 102 SARD patients (mean age: 40.3 years; 89.2% female), including 60 SLE, 32 RA and 10 other SARDs, were identified. Of these, 87 (85.3%) were infected with SARS-CoV-2. We found that the BA.5.2 and BF.7 antibody levels of infected SARD patients were lower than those of HCs (P < 0.05). Sixty-five (63.7%) patients had at least one dose of a SARS-CoV-2 vaccine. SARD patients with at least two doses of SARS-CoV-2 vaccine had a higher level of BA.5.2 and BF.7 antibodies than the unvaccinated group (P < 0.05). There was no evidence for a significant inhibitory effect of glucocorticoids (GCs) on the BA.5.2 and BF.7 Omicron variant antibody levels in SARD patients. SLE patients using biologic DMARDs had a lower BA.5.2 Omicron variant antibody level than patients using GCs and/or HCQ. Conclusion These data suggest that patients with SARDs had a lower antibody response than HCs after Omicron infection.

Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis

Risk of COVID-19 among Unvaccinated and Vaccinated Patients with Systemic Lupus Erythematosus: a General Population Study

COVID-19 vaccination questionnaire in patients with systemic lupus erythematosus: an observational study

SARS-CoV-2 Antibody Isotypes in Systemic Lupus Erythematosus Patients Prior to Vaccination: Associations With Disease Activity, Antinuclear Antibodies, and Immunomodulatory Drugs During the First Year of the Pandemic

Antibody Responses Following the Surge of SARS-CoV-2 Omicron Infection among Patients with Systemic Autoimmune Rheumatic Diseases.

Immunogenicity of Inactivated SARS-CoV-2 Vaccines in Patients With Rheumatoid Arthritis: A Case Series

Systemic lupus erythematosus following COVID-19 vaccination. A systematic review of case reports and case series

Efficacy and Safety of Anti-SARS-CoV-2 Antiviral Agents and Monoclonal Antibodies in Patients with SLE: A Case-Control Study

COVID‐19 Vaccination in Patients With Systemic Lupus Erythematosus: Adverse Events and Rating Agreement of Flares Between Patients and Physicians

Factors affecting different COVID-19 outcomes in patients with systemic lupus erythematosus during the second pandemic wave of COVID-19 in China

Risk of disease flares after SARS-CoV-2 mRNA vaccination in patients with systemic lupus erythematosus

Escalating SARS-CoV-2 specific humoral immune response in rheumatoid arthritis patients and healthy controls

COVID-19 Vaccination-Related Delayed Adverse Events among Patients with Systemic Lupus Erythematosus

COVID-19 in Systemic Lupus Erythematosus patients treated with belimumab: a retrospective clinical study

Safety, Tolerability, and Immunogenicity of COVID-19 Vaccines: A Systematic Review and Meta-Analysis

Implications of SARS-CoV-2 infection for patients with rheumatic disease

Anti-SARS-CoV-2 mRNA vaccination among patients living with SLE in Sweden: Coverage and clinical effectiveness

Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patients

Humoral immunity and safety of respiratory virus vaccines in systemic lupus erythematosus population: a meta-analysis based on twenty-five observational studies

COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients

A 12-month follow-up study of patients with systemic lupus erythematosus after immunization against SARS-CoV-2